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ABSTRACT 
Nowadays the prevalence of hyperuricemia has significantly increased in which serum uric acid levels are exceeding the normal range. Gout is the 
predominant clinical implication of the hyperuricemia, but many clinical investigations have confirmed that hyperuricemia is an independent risk 
factor for cardiovascular disease (CVD), hypertension, diabetes, and many other diseases. The xanthine oxidase (XO) converts hypoxanthine to 
xanthine and ultimately to uric acid, and the irreversibly accumulated uric acid causes hyperuricemia associated with gout. Hence specific and 
selective xanthine oxidase inhibitors (XOI) are potentially powerful tools for inactivating target XO in the pathogenic process of hyperuricemia 
(Gout). The objective of the current study was to overview the various XOI isolated from the microorganisms. Microorganisms have been employed 
for several decades for the large-scale production of a variety of bio-chemicals ranging from alcohol to antibiotics and as well as enzyme inhibitors. 
Currently available XOI (allopurinol and febuxostat) for the treatment of gout have been exhibiting serious side effects. Thus, there is a need to 
search for new molecules to treat hyperuricemia and its associated disorders. At present, microbes have been unexplored in the development of 
successful products for the management of XO-related diseases. Hence, the present review focused on novel XOI produced from various microbial 
species such as Actinobacteria, lichens, bacteria, endophytic fungi and mushrooms, which can be expected to play an important role in the ongoing 
transition from the empirical screening to the real rational drug design.  
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Hyperuricemia has long been established as the major etiological 
factor in various disorders such as gout, urolithiasis, chronic kidney 
disease (CKD), tumor lysis syndrome (TLS) and various 
cardiovascular diseases (CVD) [1, 2]. Hyperuricemia results due to 
high serum urate levels, which is attributed to its overproduction or 
underexcretion. Gout remains the most common among all 
pathologies associated with hyperuricemia. In India, approximately 
0.12-0.19% population being affected by gout, and its prevalence 
has been more in men aged above 50 y than premenopausal women 
as estrogen hormone helps in urate clearance [3, 4]. Gout was 
described by Hippocrates as “The disease of kings” owing to its 
association with a rich diet [5]. The xanthine oxidoreductase (XOR) 
is generally recognized as the key factor in hyperuricemia, 
recognized as the terminal enzyme of purine catabolism in humans. 
Mammalian XO (XO; EC 1.1.3.22) and xanthine dehydrogenase 
(XDH) (XDH; EC 1.1.1.204) are interconvertible forms of the same 
gene product known as XOR catalyzing the hydroxylation of 
hypoxanthine to xanthine and xanthine to uric acid [6-8]. This 
process is a source of reactive oxygen species (ROS) as a byproduct 
of uric acid, which being associated with diverse pathological events 
including inflammation, metabolic disorders, cellular aging, 
atherosclerosis, Parkinson’s disease, Alzheimer’s dementia, 
reperfusion injury of brain or heart and carcinogenesis [9-11]. The 
detailed structure, physiological and pathological role of XOR was 
reviewed previously [12]. The strategy involves the inhibition of the 
XO appears to be safer as it inhibits circulating levels of uric acid as 
well as vascular oxidative stress and associated disorders. Till date, 
only allopurinol, a purine analog, Febuxostat and Topiroxostat, non-
purine based selective inhibitors have been clinically approved as 
XO inhibitors [13]. Unfortunately, allopurinol is being associated 
with an infrequent but severe hypersensitivity [14]. Clinically non-
purine analogs (Febuxostat and Topiroxostat) provides greater 
hyperuricemic activity and less toxicity than allopurinol. However, 
hypersensitivity reactions of febuxostat also reported [15]. 
Nevertheless, topiroxostat exhibits high bioavailability and safety in 
humans, but side effects are not well explored owing to the short 
duration of clinical use in Japan [16]. In view of the drawbacks of 
existing therapies, there is a need to develop novel selective 
inhibitors of XO. Plants have served as an excellent source of novel 
medicinal compounds [17]. However, the inherent bottleneck 
encountered by the pharmaceutical industry in their bulk 
production as it requires huge quantities of biomass for their 
extraction which eventually threatens the existence of these plants. 
Moreover, enzyme inhibitors isolated from microbial sources are 
potent low molecular weight compounds derived from the 
hydrolysis of macromolecular substances when compared to 
inhibitors derived from plants and animals [18]. 
Several review articles focusing on the XOI of diverse sources such 
as plants, synthetic analogs have been published, serving as a 
starting point for exploration [19-23]. Thus the alternative 
resources were embattled to substitute these Phyto medicinals. It 
has been amply demonstrated by various studies that the 
metabolites produced by microorganisms, in particular, are 
recognized as a resource for numerous therapeutic moieties [24]. 
Therefore the objective of our present review is to summarize the 
various XOI derived from microbial origin. This is the first review 
exploring the updates of various XOI from microorganisms.  
XOI from various microbial sources 
Since several decades XOI has been screened and synthesized from 
various sources (fig. 1). Selected microorganisms, including bacteria, 
fungi, and yeasts have been globally studied for the bio-synthesis of 
economically valuable preparations of various enzymes and enzyme 
inhibitors for commercial applications [25, 26]. In view of their 
medicinal potential, they have been screened for the isolation of XOI.  
Bacteria 
Two specific XOI has been isolated from the culture filtrate of 
Alcaligenes aquamarinus No.655, and Bacillus cereus No. A-73 strains 
[27]. One among is identified as 2,8-dihydroxy adenine which was 
synthesized newly by microbial route (Alcaligenes aquamarinus 
No.655), but previously by chemical route [28]. The inhibitor has 
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shown 50% inhibition at a concentration of 3 x 10-6 M (0.5 g/ml) on 
rat liver XO and 2 x 10-6 M (0.33 g/ml) on milk XO, respectively. As 
well as another strain identified as Bacillus cereus produced 5-
formyluracil, a potent XOI, reported previously by microbial route 
[18]. 
A potent XOI, alkalone was identified and purified from the 
fermentation broth of a marine bacteria, Agrobacterium 
aurantiacum N-81 106[29]. When cultivation conditions of A. 
aurantiacum N-81 106 were changed using a 1000 liter fermenter, 
alkalone was not produced, and another strong XOI, Hydroxy 
alkalone, was found to be produced instead of akalone and IC50 value 
was 4.6 µm against XO [30].  
A new method was explored to isolate the novel XOI from the 
fermentation broth of Lactobacillus rhamnosus [31] and furthermore 
51 novel Acetobacter and Gluconobacter strains were screened to 
isolate XOI. Nevertheless, only seven strains have produced the 
inhibitors showing the more than 30% inhibition. In particular 
Acetobacter pasteurianus strain, AHUO1 has shown 73.6% inhibition 
[32, 33].  
 
 
Fig. 1: Various sources of XO inhibitors (Self-designed) 
 
Actinobacteria 
Actinobacteria especially Streptomyces is a proven source of 
microbial enzyme inhibitors. A new compound, 5-formyl uracil has 
been isolated from the culture broth of Streptomyces species and has 
shown strong inhibition against XO [18]. This is the only report on 
actinobacteria as a source of XOI.  
Lichens 
Lichens are fungal species which are obligate symbionts in plants. 
Lichens have long been recognized to contain bioactive compounds. 
Many natural lichens and cultured lichens have been screened for 
their biological activities, and several novel compounds were also 
isolated and identified. The phenolics and oxidative derivatives 
found in the lichens might be responsible for the inhibition of 
xanthine oxidase [34, 35]. The natural thallus of Bulbothrix 
setschwanensis was screened for bioactive compounds and found to 
be composed of mycobiont and photobiont-producing atranorin (a 
depside) and salazinic acid (a depsidone)[36]. It was reported that 
the acetone extract of the natural thallus and cultured tissue of B. 
setschwanensis was found to have inhibitory activity on the XO. The 
IC50 value was identified as 44.7 and 52.1µg/ml for cultured tissue 
and natural thallus respectively [37]. Furthermore, recently 31 
species of lichens belong to Graphidaceae were reported for their 
ability to inhibit XO. Among that Graphina glaucorufa, G. multistricta, 
G. salacinilabiata, G. assamensis, G. nakanishiana, and Phaeographosis 
indica has shown strong inhibition of XO with the lower IC50 value of 
3-4.8 µg/ml when compared to standard allopurinol having an IC50 
value of 6.37µg/ml [38].  
Endophytic fungi 
Over the last two decades, endophytic fungi have been 
demonstrated to be a rich and reliable source of novel bioactive 
compounds possessing antimicrobial, anticancer, neuroprotective, 
insulin-mimetic, anti-oxidant properties that may foster great 
medicinal or agricultural potentials [39, 40]. Endophytic fungi 
colonize the plants internally without apparent symptoms of their 
ubiquitous existence and are increasingly being prospected as 
underexplored resources of novel bioactive compounds [41]. 
Exploring endophytic fungi for XO inhibition is a nascent area with 
very scanty preliminary data [42]. Together medicinal plants, 
endophytic fungi offer themselves as a relatively reliable source of 
natural products which could inhibit XO and probably enters the 
medical field as an antihyperuricemic drug. Fusaruside is a 
chemically a new cerebroside, characterized from the chloroform-
methanol (1:1) extract of Fusarium sp. IFB-121, an endophytic 
fungus in Quercus variabilis with an IC50 value of 43.8±3.6 µm. In 
addition to Fusaruside, a known cerebroside isolated from Fusarium 
sp. has shown XO inhibitory activity with an IC50 value of 55.5±1.8 
µm [43]. As well as phenolic compounds isolated from endophytic 
chaetornium sp residing in Nerium oleander L (Apocyanaceae) has 
exhibited an XO inhibitory activity and the IC50 value was found to be 
109.8 µg/ml [44].  
Recently XOI has been isolated from novel species of Muscodor, 
sterile endophytic fungi. Culture filtrates of 7 species of Muscodor 
isolated from Cinnamomum and Aegle marmelos. Amongst, the 
chloroform extract of M. darjeelingensis exhibited the maximum XOI 
with an IC50 of 0.54l g/ml which was much lower to allopurinol but 
higher when compared to febuxostat. Nevertheless, 88% reduction 
in uric acid production by the extract of M. darjeelingensis was 
similar to allopurinol [45]. Similarly, 19 fungal endophytes were 
isolated from the medicinal plant Tinospora cordifolia and evaluated 
for their XO inhibitory activity. In the qualitative assay, Out of 19 
fungal endophytes, 7 endophytes exhibited>30% XO inhibition, of 
which isolates #1 TCSTITPLM, #53 TCSTITPLM, #105 TCSTITPLM, 
and #83 TCSTITPLM were found to exhibit XO inhibition in the 
range of 38–45%. Ethyl acetate and chloroform extract of #1 
TCSTITPLM and #53 TCSTITPLM demonstrated potent XO 
inhibitory action of 69 and 63% respectively [46]. new culture 
filtrates of 42 endophytic fungi were screened for XO inhibition in 
the process of searching for new XOI. The chloroform extract of 
culture filtrate #1048 AMSTITYEL has exhibited the potential 
inhibition of XO with an IC50 value of 0.61 μg/ml which was better 
than allopurinol (IC50 of 0.937 μg/ml) but lower than febuxostat 
(IC50 of 0.076 μg/ml). The endophyte was identified as Lasiodiplodia 
pseudotheobromae isolated from Aegle marmelos [47].  
Furthermore, endophytic fungi, Aspergillus niger IFB-E003 isolated 
from Cyndon dactylon has screened for XOI. The fraction of the 
Aspergillus niger extract has shown four known compounds 
naphtha ᵧ pyrones such as rubrofusarin B, fonsecinone A, a 
sperpyrone B, and auraspernone A. Amongst, auraspernone A has 
shown XO inhibition with an IC50 value of 10.9 μmol. Moreover, 
rubrofusarin B and auraspernone A were also proved as strong co-
inhibitors on XO [42].       
Mushrooms 
Over the decade’s mushrooms have been used not only as a source 
of food, but also remarkable and unexplored source of new 
biologically active natural products [48]. Mushrooms belong to 
Basidiomycota of fungi, has received great interest because it 
contains a large number of biologically active compounds such as 
polysaccharides, glycoproteins, triterpenes, and antibiotics [49]. 
Recently mushrooms are being explored as a potential source of XO 
inhibitors. Flavonoids and polyphenolic crude extracts have been 
reported to exhibit XO inhibition [50, 51] besides the different 
flavonoid containing plant species, mushrooms also represents a 
potential source of such compounds [52, 53]. An unusual compound, 
5-methyl-3 (2H)–furanone derivative (inotilione) was isolated from 
the fruiting body of the mushroom Inonotus sp. which has exhibited 
XO inhibition. The fruiting bodies were subjected to ethanol and 
chloroform-methanol extraction and purification to isolate the 
compounds exhibiting XO inhibition [54].  
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The acetonic, methanolic and hot water extracts from the fruiting 
bodies of Pleurotus salmoneoshamineus and P. nebrodensis were 
reported to have XO inhibition which was found to be increased with 
increasing concentrations [55, 56]. In a similar way, a new 
compound was purified from the aqueous extract of Pleurotus 
ostreaus and has exhibited XO inhibitory activity with an IC50 value 
of 0.9 mg/ml [57].  
A new species of central European Phellinoid Hymenochaetaceae 
(Phellinus sesulato) have screened for XOI. The in vitro antioxidant and 
XO inhibitory assays demonstrated that most of the selected species 
possess remarkable antioxidant and XO inhibitory action [58].  
A new study was reported in which fermented mushroom water 
extracts with lactic acid bacteria were exhibited XO inhibition. 
Fermented mushroom water extracts have increased the free radical 
scavenging activity, and the antioxidant activity of fermented 
mushroom extracts was further confirmed by XO inhibition [59]. As 
well as the above species XO inhibitory activity of aqueous and 
organic (n-hexane, chloroform, and 50% methanol) extracts of 47 
wild-growing mushrooms native to Hungary have been reported. 
Among the 47 species, Hypholoma fasciculare (IC50= 67.76 ± 11.05 
μg/ml), Suillus grevillei (IC50= 13.28 ± 1.58 μg/ml), and Tricholoma 
populinum (IC50= 85.08 ± 15.02 μg/ml) were exhibited high 
inhibitory activity [60]. 
CONCLUSION 
The disease burden of hyperuricemia remains a major problem and 
may be increasing day by day. As described in this article, the rich 
diversity of microorganisms with their unique characteristics emerged 
as a potential source for the discovery of XOI. This review is a fine 
effort to compile and present XOI from microbial sources to encourage 
further research to use natural microbial XOI in the management and 
treatment of hyperuricemia and other associated disorders. 
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